Oncotarget

Brief Reports:

Pilot study of a pediatric metronomic 4-drug regimen

Nicolas André _, Sylvie Abed, Daniel Orbach, Corinne Armari Alla, Laetitia Padovani, Eddy Pasquier, Jean Claude Gentet and Arnauld Verschuur

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2011; 2:960-965. https://doi.org/10.18632/oncotarget.358

Metrics: PDF 2247 views  |   HTML 2759 views  |   ?  


Abstract

Nicolas André1,2, Sylvie Abed1, Daniel Orbach3, Corinne Armari Alla4, Laetitia Padovani5, Eddy Pasquier2,6, Jean Claude Gentet1, Arnauld Verschuur1,2

1 Service d’Hématologie et Oncologie Pédiatrique, Hôpital pour Enfants de La Timone, Marseille, France

2 Metronomics Global Health Initiative, Marseille, France

3 Service d’Oncologie Pédiatrique, Institut Curie, Paris, France

4 Service d’Oncologie Pédiatrique, Grenoble, France

5 Service de Radiothérapie, Hôpital de La Timone, Marseille, France

6 Children’s Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW, Australia

Received: November 18, 2011; Accepted: December 5, 2011; Published: December 5, 2011;

Keywords: Cmetronomic chemotherapy, pediatric oncology, angiogenesis, immune system

Correspondence:

Nicolas André MD, PhD, email:

Abstract

Background: Metronomic chemotherapy (MC) is defined as the frequent administration of chemotherapy at doses below the maximal tolerated dose and with no prolonged drug-free break. MC is gaining interest as an alternative strategy to fight resistant cancer.

Objective: to assess the safety of 4 drug MC regimen in paediatric patients with refractory or relapsing various tumour types.

Setting: From November 2008 to December 2010, in three academic paediatric oncology centers, 16 children (median age 12 years old; range 5.5-20) were included in this pilot study. This treatment was proposed to children with refractory disease for whom no further effective treatments were available. Most frequent diagnosis were medulloblastoma/cerebral PNET (5) osteosarcoma (5), and one case each of nephroblastoma, high grade glioma, Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma and kidney rhabdoid tumour. The MC regimen consisted in cycles of 56 days (8 weeks) with weekly vinblastine 3 mg/m2 (week 1-7), daily cyclophosphamide 30 mg/m2 (days 1-21), and twice weekly methotrexate 10 mg/m² (days 21-42), and daily celecoxib 100 mg to 400 mg twice daily (days1-56) followed by a 2-weeks chemotherapy break. Adverse events were determined through laboratory analysis and investigator observations.

Results: One objective response was observed in a patient with Hodgkin lymphoma, and 4 patients experienced disease stabilization and continued their treatment for 3 cycles (24 weeks) or more. At last follow-up, 7 patients (43%) are alive including 1 still undergoing treatment.  During the overall 36 cycles of treatments received by patients, 4 grade IV toxicities and 24 grade III toxicities were observed in11 cycles in  only 10 different patients.

Conclusion: The metronomic regimen we report here was well tolerated and associated with disease stabilization. This regimen is currently being evaluated in a national multicenter phase II study.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 358